Klaus Sahora

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3864883/publications.pdf

Version: 2024-02-01

516710 552781 1,483 26 16 26 h-index citations g-index papers 31 31 31 2097 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Surgery for chronic pancreatitis: the comparison of two high-volume centers reveals lack of a uniform operative management. Langenbeck's Archives of Surgery, 2021, , 1.	1.9	2
2	Systemic Immune-Inflammation Index (SII) Predicts Poor Survival in Pancreatic Cancer Patients Undergoing Resection. Journal of Gastrointestinal Surgery, 2020, 24, 610-618.	1.7	100
3	The Prognostic Index Independently Predicts Survival in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Resection. Annals of Surgical Oncology, 2020, 27, 2017-2024.	1.5	11
4	Management of cystic pancreatic lesions. European Surgery - Acta Chirurgica Austriaca, 2019, 51, 121-125.	0.7	2
5	Sarcopenia and sarcopenic obesity are independent adverse prognostic factors in resectable pancreatic ductal adenocarcinoma. PLoS ONE, 2019, 14, e0215915.	2.5	57
6	Long-term Risk of Pancreatic Malignancy in Patients With Branch Duct Intraductal Papillary Mucinous Neoplasm in a Referral Center. Gastroenterology, 2017, 153, 1284-1294.e1.	1.3	189
7	Preoperative biliary drainage does not increase major complications in pancreaticoduodenectomy: a large single center experience from the <scp>Massachusetts</scp> General Hospital. Journal of Hepato-Biliary-Pancreatic Sciences, 2016, 23, 181-187.	2.6	53
8	Discordance Between Perioperative Antibiotic Prophylaxis and Wound Infection Cultures in Patients Undergoing Pancreaticoduodenectomy. JAMA Surgery, 2016, 151, 432.	4.3	95
9	Intraductal papillary mucinous neoplasms. Current Opinion in Gastroenterology, 2015, 31, 424-429.	2.3	17
10	The Proteome of Postsurgical Pancreatic Juice. Pancreas, 2015, 44, 574-582.	1.1	15
11	IPMN Involving the Main Pancreatic Duct. Annals of Surgery, 2015, 261, 976-983.	4.2	114
12	Effects of Comorbidities on Outcomes of Patients With Intraductal Papillary Mucinous Neoplasms. Clinical Gastroenterology and Hepatology, 2015, 13, 1816-1823.	4.4	54
13	The effect of antecolic versus retrocolic reconstruction on delayed gastric emptying afterÂclassic non–pylorus-preserving pancreaticoduodenectomy. American Journal of Surgery, 2015, 209, 1028-1035.	1.8	34
14	HER2 Gene Amplification and Protein Expression in Pancreatic Ductal Adenocarcinomas. Applied Immunohistochemistry and Molecular Morphology, 2014, 22, 146-152.	1.2	23
15	Preparing for Prospective Clinical Trials: A National Initiative of an Excellence Registry for Consecutive Pancreatic Cancer Resections. World Journal of Surgery, 2014, 38, 456-462.	1.6	10
16	Impact of the Reconstruction Method on Delayed Gastric Emptying After Pylorusâ€Preserving Pancreaticoduodenectomy: A Prospective Randomized Study. World Journal of Surgery, 2014, 38, 465-475.	1.6	44
17	Distal Gastrectomy in Pancreaticoduodenectomy is Associated with Accelerated Gastric Emptying, Enhanced Postprandial Release of GLP-1, and Improved Insulin Sensitivity. Journal of Gastrointestinal Surgery, 2014, 18, 52-59.	1.7	12
18	Understanding Hospital Readmissions After Pancreaticoduodenectomy: Can We Prevent Them?. Journal of Gastrointestinal Surgery, 2014, 18, 137-145.	1.7	88

#	Article	IF	CITATION
19	Phosphorylation of <scp>STAT</scp> 3 correlates with <scp>HER</scp> 2 status, but not with survival in pancreatic ductal adenocarcinoma. Apmis, 2014, 122, 476-481.	2.0	7
20	Not all mixed-type intraductal papillary mucinous neoplasms behave like main-duct lesions: Implications of minimal involvement of the main pancreatic duct. Surgery, 2014, 156, 611-621.	1.9	65
21	Natural History and Malignant Change of Main Duct IPMN. , 2014, , 11-17.		0
22	Timing of Resection of Main-Duct IPMN. , 2014, , 153-161.		0
23	Branch Duct Intraductal Papillary Mucinous Neoplasms. Annals of Surgery, 2013, 258, 466-475.	4.2	254
24	NeoGemOx: Gemcitabine and oxaliplatin as neoadjuvant treatment for locally advanced, nonmetastasized pancreatic cancer. Surgery, 2011, 149, 311-320.	1.9	101
25	NeoGemTax: Gemcitabine and Docetaxel as Neoadjuvant Treatment for Locally Advanced Nonmetastasized Pancreatic Cancer. World Journal of Surgery, 2011, 35, 1580-1589.	1.6	50
26	Gadobenate Dimeglumine–enhanced 3.0-T MR Imaging versus Multiphasic 64–Detector Row CT: Prospective Evaluation in Patients Suspected of Having Pancreatic Cancer. Radiology, 2011, 259, 757-766.	7.3	79